Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Solid Tumors
NCT03065387Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2017
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of neratinib in solid tumor (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Oct 2017; status: terminated.
02
Drugs
neratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03065387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065387.